XML 37 R21.htm IDEA: XBRL DOCUMENT
v3.8.0.1

Common Stock | 12 Months Ended
--- | ---
Dec. 31, 2017
Equity [Abstract] |
Common Stock | 13. Common Stock National Oilwell Varco has authorized 1 billion shares of $0.01 par value common stock. The Company also has authorized 10 million shares of $0.01 par value preferred stock, none of which is issued or outstanding. Cash dividends aggregated $76 million and $230 million for the years ended December 31, 2017 and 2016, respectively. The declaration and payment of future dividends is at the discretion of the Company’s Board of Directors and will be dependent upon the Company’s results of operations, financial condition, capital requirements and other factors deemed relevant by the Company’s Board of Directors. Total compensation cost that has been charged against income for all share-based compensation arrangements was $124 million, $107 million and $109 million for 2017, 2016 and 2015, respectively. The total income tax benefit recognized in the consolidated statements of income for all share-based compensation arrangements was $24 million, $30 million and $32 million for 2017, 2016 and 2015, respectively. Under the terms of National Oilwell Varco’s Long-Term Incentive Plan, as amended during the second quarter of 2016, 69.4 million shares of common stock are authorized for the grant of options to officers, key employees, non-employee directors and other persons. The Plan provides for the granting of stock options, performance-based share awards, restricted stock, phantom shares, stock payments and stock appreciation rights (“SARs”). The Plan is now subject to a fungible ratio concept, such that the issuance of stock options and SARs reduces the number of available shares under the Plan on a 1-for-1 basis, and the issuance of other awards reduces the number of available shares under the Plan on a 3-for-1 basis. At December 31, 2017, approximately 17.8 million shares were available for future grants. Stock Options Options granted under our stock option plan generally vest over a three-year period starting one year from the date of grant and expire ten years from the date of grant. The purchase price of options granted may not be less than the closing market price of National Oilwell Varco common stock on the date of grant. We also have an inactive stock option plan that was acquired in connection with the acquisition of Grant Prideco in 2008. We converted the outstanding stock options under this plan to options to acquire our common stock and no further options are being issued under this plan. Stock option information summarized below includes amounts for the National Oilwell Varco Long-Term Incentive Plan and stock plans of acquired companies. Options outstanding at December 31, 2017 under the stock option plans have exercise prices between $23.94 and $77.99 per share, and expire at various dates from February 8, 2018 to April 1, 2027. The following summarizes options activity:
|  | Years Ended December 31, |
|  | 2017 |  |  | 2016 |  |  | 2015 |
|  | Number |  |  | Average |  |  | Number |  |  | Average |  |  | Number |  |  | Average |
|  | of |  |  | Exercise |  |  | of |  |  | Exercise |  |  | of |  |  | Exercise |
|  | Shares |  |  | Price |  |  | Shares |  |  | Price |  |  | Shares |  |  | Price |
Shares under option at beginning of year |  |  | 17,439,060 |  |  | $ | 54.08 |  |  |  | 15,430,307 |  |  | $ | 59.50 |  |  |  | 10,881,133 |  |  | $ | 61.22 |
Granted |  |  | 6,961,041 |  |  |  | 36.51 |  |  |  | 3,672,411 |  |  |  | 28.26 |  |  |  | 5,746,153 |  |  |  | 54.74 |
Forfeited |  |  | (1,482,531 | ) |  |  | 55.22 |  |  |  | (1,517,065 | ) |  |  | 49.95 |  |  |  | (886,356 | ) |  |  | 62.73 |
Exercised |  |  | (445,523 | ) |  |  | 29.83 |  |  |  | (146,593 | ) |  |  | 28.53 |  |  |  | (310,623 | ) |  |  | 22.56 |
Shares under option at end of year |  |  | 22,472,047 |  |  | $ | 48.99 |  |  |  | 17,439,060 |  |  | $ | 54.08 |  |  |  | 15,430,307 |  |  | $ | 59.50 |
Exercisable at end of year |  |  | 14,309,944 |  |  | $ | 55.00 |  |  |  | 9,828,897 |  |  | $ | 61.56 |  |  |  | 7,498,414 |  |  | $ | 60.30 |
The following summarizes information about stock options outstanding at December 31, 2017:
|  | Weighted-Avg |  |  | Options Outstanding |  |  | Options Exercisable |
|  | Remaining |  |  |  |  |  | Weighted-Avg |  |  |  |  |  | Weighted-Avg |
Range of Exercise Price |  | Contractual Life |  |  | Shares |  |  | Exercise Price |  |  | Shares |  |  | Exercise Price |
$23.94 - $55.00 |  |  | 7.55 |  |  |  | 15,797,683 |  |  | $ | 40.25 |  |  |  | 7,635,580 |  |  | $ | 42.19 |
$55.01 - $70.00 |  |  | 5.09 |  |  |  | 4,301,953 |  |  |  | 66.20 |  |  |  | 4,301,953 |  |  |  | 66.20 |
$70.01 - $77.99 |  |  | 3.59 |  |  |  | 2,372,411 |  |  |  | 75.94 |  |  |  | 2,372,411 |  |  |  | 75.94 |
Total |  |  | 6.66 |  |  |  | 22,472,047 |  |  | $ | 48.99 |  |  |  | 14,309,944 |  |  | $ | 55.00 |
The weighted-average fair value of options granted during 2017, 2016 and 2015, was approximately $9.68, $6.44 and $15.41 per share, respectively, as determined using the Black-Scholes option-pricing model. The total intrinsic value of options exercised during 2017 and 2016 was $13 million and $4 million, respectively. The determination of fair value of share-based payment awards on the date of grant using an option-pricing model is affected by our stock price as well as assumptions regarding a number of highly complex and subjective variables. These variables include, but are not limited to, the expected stock price volatility over the term of the awards, and actual and projected employee stock option exercise activity. The use of the Black Scholes model requires the use of actual employee exercise activity data and the use of a number of complex assumptions including expected volatility, risk-free interest rate, expected dividends and expected term.
|  | Years Ended December 31, |
|  | 2017 |  |  | 2016 |  |  | 2015 |
Valuation Assumptions: |  |  |  |  |  |  |  |  |  |  |  |
Expected volatility |  |  | 36.1 | % |  |  | 48.6 | % |  |  | 49.1 | %
Risk-free interest rate |  |  | 2.2 | % |  |  | 1.2 | % |  |  | 1.5 | %
Expected dividend yield |  |  | 0.6 | % |  |  | 6.5 | % |  |  | 3.4 | %
Expected term (in years) |  |  | 3.0 |  |  |  | 3.0 |  |  |  | 3.0 |
The Company used the actual volatility for traded options for the past 10 years prior to option date as the expected volatility assumption required in the Black Scholes model. The risk-free interest rate assumption is based upon observed interest rates appropriate for the term of our employee stock options. The dividend yield assumption is based on the history and expectation of dividend payouts. The estimated expected term is based on actual employee exercise activity for the past ten years. Forfeitures are accounted for as they occur. The following summary presents information regarding outstanding options at December 31, 2017 and changes during 2017 with regard to options under all stock option plans:
|  |  |  |  |  |  |  | Weighted |  |  |  |
|  |  |  |  | Weighted- Average |  |  | Remaining Contractual |  |  |  |
|  | Shares |  |  | Exercise Price |  |  | Term (years) |  |  | Aggregate Intrinsic Value |
Outstanding at December 31, 2016 |  |  | 17,439,060 |  |  | $ | 54.08 |  |  |  | 5.42 |  |  | $ | 6,700,856 |
Granted |  |  | 6,961,041 |  |  | $ | 36.51 |  |  |  |  |  |  |  |  |
Forfeited |  |  | (1,482,531 | ) |  | $ | 55.22 |  |  |  |  |  |  |  |  |
Exercised |  |  | (445,523 | ) |  | $ | 29.83 |  |  |  |  |  |  |  |  |
Outstanding at December 31, 2017 |  |  | 22,472,047 |  |  | $ | 48.99 |  |  |  | 6.66 |  |  | $ | 34,186,368 |
Exercisable at December 31, 2017 |  |  | 14,309,944 |  |  | $ | 55.00 |  |  |  | 5.70 |  |  | $ | 15,557,324 |
At December 31, 2017, total unrecognized compensation cost related to nonvested stock options was $36 million. This cost is expected to be recognized over a weighted-average period of two years. The total fair value of stock options vested in 2017, 2016 and 2015 was approximately $70 million, $61 million and $72 million, respectively. Cash received from option exercises for 2017, 2016 and 2015 was $13 million, $4 million and $7 million, respectively. The actual tax benefit (expense) realized for the tax deductions from option exercises totaled $(2) million, nil and $3 million for 2017, 2016 and 2015, respectively. Stock Appreciation Rights On December 20, 2017, the Company made a tender offer to exchange SARs issued to certain employees on February 24, 2016 (“2016 SARs”) for cash, amended SARs, and new stock options. The transaction was structured to provide the employees an equal long-term incentive compensation value, while alleviating volatility in the Company’s earnings caused by required mark-to-market accounting on outstanding SARS. Of the outstanding 2016 SARs, 94.75% were exchanged resulting in a total cash payment of $14 million and granting of 3,613,707 new stock options on the exchange date with an exercise price of $34.32 and a fair value of $8.47, with vesting matched to the exchanged 2016 SARs. As a result of exchanging the 2016 SARs for cash and new stock options, the Company recorded $11 million of compensation expense and an increase of $20 million to additional paid-in capital in the fourth quarter of 2017. The following summary presents information regarding outstanding SARs:
|  | Year Ended December 31, |
|  | 2017 |  |  | 2016 |
|  | Number |  |  | Average |  |  | Number |  |  | Average |
|  | of |  |  | Exercise |  |  | of |  |  | Exercise |
|  | Shares |  |  | Price |  |  | Shares |  |  | Price |
Shares under SARs at beginning of year |  |  | 4,341,740 |  |  | $ | 28.32 |  |  |  | — |  |  | $ | — |
Granted |  |  | 14,400 |  |  |  | 38.86 |  |  |  | 4,618,400 |  |  |  | 28.32 |
Forfeited |  |  | (283,822 | ) |  |  | 28.35 |  |  |  | (276,660 | ) |  |  | 28.24 |
Exercised |  |  | (2,578,629 | ) |  |  | 34.72 |  |  |  | — |  |  |  | — |
Shares under SARs at end of year |  |  | 1,493,689 |  |  | $ | 28.41 |  |  |  | 4,341,740 |  |  | $ | 28.32 |
Exercisable at end of year |  |  | 75,102 |  |  | $ | 28.33 |  |  |  | — |  |  | $ | — |
As of December 31, 2017, there was $16 million of unrecognized compensation expense related to nonvested SARs, which is expected to be recognized over a weighted-average period of approximately two years. The expense recognized in 2017 and 2016 was $8 million and $20 million, respectively. The liability for cash-settled SARs was $2 million at December 31, 2017. Restricted Shares The Company issues restricted stock awards and restricted stock units to officers and key employees in addition to stock options. On February 22, 2017, the Company granted 1,504,450 shares of restricted stock and restricted stock units with a fair value of $38.86 per share; and performance share awards to senior management employees with potential payouts varying from zero to 388,380 shares. The restricted stock and restricted stock units vest on the third anniversary of the date of grant or in three equal annual installments commencing on the first anniversary of the date of grant. The performance share awards can be earned based on performance against established goals over a three-year performance period. The performance share awards are based entirely on a TSR (total shareholder return) goal. Performance against the TSR goal is determined by comparing the performance of the Company’s TSR with the TSR performance of the members of the OSX index for the three-year performance period. On May 17, 2017, the Company granted 36,701 restricted stock awards with a fair value of $33.38 per share. The awards were granted to non-employee members of the board of directors and vest on the first anniversary of the grant date. The following summary presents information regarding outstanding restricted shares:
|  | Years Ended December 31, |
|  | 2017 |  |  | 2016 |  |  | 2015 |
|  |  |  |  | Weighted- |  |  |  |  |  | Weighted- |  |  |  |  |  | Weighted- |
|  | Number |  |  | Average |  |  | Number |  |  | Average |  |  | Number |  |  | Average |
|  | of |  |  | Grant Date |  |  | of |  |  | Grant Date |  |  | of |  |  | Grant Date |
|  | Units |  |  | Fair Value |  |  | Units |  |  | Fair Value |  |  | Units |  |  | Fair Value |
Nonvested at beginning of year |  |  | 4,563,983 |  |  | $ | 41.10 |  |  |  | 1,969,250 |  |  | $ | 61.53 |  |  |  | 1,569,141 |  |  | $ | 73.73 |
Granted |  |  | 1,738,589 |  |  |  | 38.74 |  |  |  | 3,384,325 |  |  |  | 31.59 |  |  |  | 954,075 |  |  |  | 53.27 |
Vested |  |  | (1,018,206 | ) |  |  | 34.84 |  |  |  | (565,202 | ) |  |  | 29.32 |  |  |  | (405,327 | ) |  |  | 54.30 |
Forfeited |  |  | (394,688 | ) |  |  | 55.22 |  |  |  | (224,390 | ) |  |  | 49.95 |  |  |  | (148,639 | ) |  |  | 62.73 |
Nonvested at end of year |  |  | 4,889,678 |  |  | $ | 37.04 |  |  |  | 4,563,983 |  |  | $ | 41.10 |  |  |  | 1,969,250 |  |  | $ | 61.53 |
The weighted-average grant day fair value of restricted stock awards and restricted stock units granted during the years ended 2017, 2016 and 2015 was $38.74, $31.59 and $53.27 per share, respectively. There were 1,018,206; 565,202 and 405,327 restricted stock awards that vested during 2017, 2016 and 2015, respectively. At December 31, 2017, there was approximately $99 million of unrecognized compensation cost related to nonvested restricted stock awards and restricted stock units, which is expected to be recognized over a weighted-average period of two years.

X
- References No definition available. + Details
Name: | us-gaap_EquityAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -URI http://asc.fasb.org/topic&trid=2208762 + Details
Name: | us-gaap_StockholdersEquityNoteDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration